-
Jan 19, 2025 | 
cgtlive.com | Georg Schett |Noah Stansfield
Over the past few years, chimeric antigen receptor T-cell (CAR-T) therapy, which originally got its start in oncology, had become a burgeoning area of interest for the treatment of autoimmune disease. With a large number of new clinical trials having launched in 2023 and 2024, the field is rapidly evolving.
-
Jan 15, 2025 | 
nature.com | Yixuan Li |Georg Schett |Yewei Jia
AbstractOsteocytes are the main cells in mineralized bone tissue. Elevated osteocyte apoptosis has been observed in lytic bone lesions of patients with multiple myeloma. However, their precise contribution to bone metastasis remains unclear. Here, we investigated the pathogenic mechanisms driving melanoma-induced osteocyte death. Both in vivo models and in vitro assays were combined with untargeted RNA sequencing approaches to explore the pathways governing melanoma-induced osteocyte death.
-
Jan 14, 2025 | 
cgtlive.com | Georg Schett |Noah Stansfield
“Imagine you can abrogate the whole disease with a single infusion and do this early and prevent organ damage. I think that concept is very appealing. At the moment, I think we are not there because [earlier on] data on safety were basically not present, but now [those data] are actually coming up more and more.
-
Jan 8, 2025 | 
nature.com | Georg Schett |Biliang Hu
Dear Editor, Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by symmetric synovial inflammation leading to progressive disability.1 Treatment of RA has been revolutionized by the development of monoclonal antibodies against cytokines (e.g., tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6)) as well as B-cells (e.g., CD20-targeted antibody rituximab), resulting in better disease control.2 However, up to 30% of RA patients still escape therapeutic responses...
-
Dec 1, 2024 | 
jrheum.org | Laura Coates |Georg Schett |Chenchen Wang |Pamela F. Weiss
Key Indexing Terms:ankylosing spondylitisoutcomesspondyloarthropathyIntroductionThe advances in our understanding of pathogenesis, novel therapeutics, and nonpharmacologic interventions have revolutionized the management of axial spondyloarthritis (axSpA).
-
Nov 25, 2024 | 
cgtlive.com | Georg Schett |Noah Stansfield |Victoria Johnson
At the American College of Rheumatology (ACR) Convergence 2024 in Washington, DC, Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg, presented data from 2 studies evaluating CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies in patients with a variety of refractory autoimmune and rheumatic diseases.
-
Nov 20, 2024 | 
cgtlive.com | Georg Schett |Victoria Johnson
This interview originally appeared on our sister site, HCPLive®. “The relapse rate is very low, and there have been occasional relapses reported in the field by other studies, but also with low dose CAR T-cell therapy, because that was the starting dose.
-
Nov 13, 2024 | 
nature.com | Arif B. Ekici |Stefan Wirtz |Georg Schett
AbstractGerminal centers where B cells undergo clonal expansion and antibody affinity maturation are hypoxic microenvironments. However, the function of hypoxia-inducible factor (HIF)-1α in immunoglobulin production remains incompletely characterized. Here, we demonstrated that B cells lacking HIF-1α exhibited significantly lower glycolytic metabolism and impaired IgA production.
-
Oct 16, 2024 | 
jrheum.org | Laura Coates |Georg Schett |Chenchen Wang |Pamela F. Weiss
AbstractA program focused on pathogenesis, clinical trial design, and nonpharmacologic mind-body therapy for of spondyloarthritis (SpA) was presented at the Spondylitis Association of America Unmet Needs Conference IV. SpA pathogenesis is incompletely understood but involves a complex set of drivers, including genetics, biomechanical stress, and microbial factors. Affected tissues may include axial and peripheral joints, entheses, skin, uvea, and intestines.
-
Sep 27, 2024 | 
science.org | Georg Schett |Thomas Ernst Dorner |Erika Gebel Berg
Our bodies are in a constant balancing act known as homeostasis. The ringleader behind all this? Autophagy, an essential lysosome-mediated degradation pathway that maintains cellular viability and death in response to various intra- and extra-cellular stress. It determines whether we remain healthy or succumb to diseases, such as cancer, Parkinson’s, and diabetes, and scientists have recently made headway in elucidating its pathways. Autophagy appears to be a double-edged sword.
